EUVIMEDEUVIMED felfedezése
Open access · CC BY 4.0

Targeting E3 ubiquitin ligases to sensitize cancer radiation therapy

Zan Chen, Wei Xu

Precision Radiation Oncology · 2019

DOI: 10.1002/pro6.1069 ↗

At a glance

Journal article in Precision Radiation Oncology, 2019. Written by Zan Chen and 1 co-authors. Cited 3 times so far (Crossref); 96 references. The full text is freely available (open access, CC BY 4.0).

AbsztraktBibliográfiai adatokCiteRelated studies

Abstract (original language)

Radiotherapy is an effective treatment for many cancer patients to eliminate malignant cells and increase survival rate. However, cancer cells can develop resistance in response to radiation through activation of signaling pathways that promote cell cycle progression, DNA damage response, cell survival, and inflammation. Various combination therapies are developed to sensitize radiotherapy by targeting key signaling proteins involved in radioresponse. The past decade has seen significant advances in the knowledge of ubiquitin signaling in cancer biology. Developing E3 ubiquitin ligase‐related molecules as novel strategies to cure cancer has become an emerging field. This review briefly discusses the potential of targeting diverse E3 ubiquitin ligases as promising strategies for radiosensitization in cancer.

Cite

APA

Chen, Z., & Xu, W. (2019). Targeting E3 ubiquitin ligases to sensitize cancer radiation therapy. Precision Radiation Oncology. https://doi.org/10.1002/pro6.1069

Vancouver

Chen Z, Xu W. Targeting E3 ubiquitin ligases to sensitize cancer radiation therapy. Precision Radiation Oncology. 2019. doi:10.1002/pro6.1069

BibTeX
@article{Chen2019,
  author = {Chen, Zan and Xu, Wei},
  title = {Targeting E3 ubiquitin ligases to sensitize cancer radiation therapy},
  journal = {Precision Radiation Oncology},
  year = {2019},
  doi = {10.1002/pro6.1069}
}
Start for free →